- Home
- ELDN vs LYEL Comparison
ELDN vs LYEL Comparison
Compare ELDN & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELDN
- LYEL
- Stock Information
- Founded
- ELDN 2004
- LYEL 2018
- Country
- ELDN United States
- LYEL United States
- Employees
- ELDN 31
- LYEL N/A
- Industry
- ELDN Biotechnology: Pharmaceutical Preparations
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- ELDN Health Care
- LYEL Health Care
- Exchange
- ELDN Nasdaq
- LYEL Nasdaq
- Market Cap
- ELDN 176.1M
- LYEL 207.7M
- IPO Year
- ELDN N/A
- LYEL 2021
- Fundamental
- Price
- ELDN $2.99
- LYEL $0.43
- Analyst Decision
- ELDN Strong Buy
- LYEL Sell
- Analyst Count
- ELDN 1
- LYEL 2
- Target Price
- ELDN $16.00
- LYEL $1.00
- AVG Volume (30 Days)
- ELDN 249.0K
- LYEL 752.1K
- Earning Date
- ELDN 05-08-2025
- LYEL 05-05-2025
- Dividend Yield
- ELDN N/A
- LYEL N/A
- EPS Growth
- ELDN N/A
- LYEL N/A
- EPS
- ELDN N/A
- LYEL N/A
- Revenue
- ELDN N/A
- LYEL $61,000.00
- Revenue This Year
- ELDN N/A
- LYEL N/A
- Revenue Next Year
- ELDN N/A
- LYEL N/A
- P/E Ratio
- ELDN N/A
- LYEL N/A
- Revenue Growth
- ELDN N/A
- LYEL N/A
- 52 Week Low
- ELDN $1.55
- LYEL $0.39
- 52 Week High
- ELDN $5.54
- LYEL $2.88
- Technical
- Relative Strength Index (RSI)
- ELDN 39.03
- LYEL 39.54
- Support Level
- ELDN $2.63
- LYEL $0.43
- Resistance Level
- ELDN $3.21
- LYEL $0.51
- Average True Range (ATR)
- ELDN 0.24
- LYEL 0.05
- MACD
- ELDN 0.03
- LYEL 0.00
- Stochastic Oscillator
- ELDN 45.24
- LYEL 23.43
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.